Cardio3 BioSciences’ Stem Cell Heart Therapy Phase III Trials Bolstered By New Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.